

Rajesh Chopra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11078790/publications.pdf>

Version: 2024-02-01

50
papers

6,096
citations

126907

33
h-index

206112

48
g-index

50
all docs

50
docs citations

50
times ranked

7618
citing authors

#	ARTICLE	IF	CITATIONS
1	Lenalidomide induces ubiquitination and degradation of CK1 β in del(5q) MDS. <i>Nature</i> , 2015, 523, 183-188.	27.8	648
2	Challenges to curing primary brain tumours. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 509-520.	27.6	540
3	Immunomodulatory agents lenalidomide and pomalidomide co -- stimulate T cells by inducing degradation of T cell repressors IKAROS and AIOLOS via modulation of the E3 ubiquitin ligase complex CRL4 ^{CRBN} . <i>British Journal of Haematology</i> , 2014, 164, 811-821.	2.5	505
4	In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. <i>Blood</i> , 2000, 96, 2419-2425.	1.4	483
5	Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. <i>Blood</i> , 2002, 99, 1071-1078.	1.4	333
6	Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. <i>Blood</i> , 2004, 104, 3865-3871.	1.4	280
7	Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. <i>Lancet</i> , 2005, 365, 1934-1941.	13.7	273
8	An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β -thalassemia. <i>Nature Medicine</i> , 2014, 20, 398-407.	30.7	245
9	Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. <i>Blood</i> , 2005, 105, 4532-4539.	1.4	228
10	The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. <i>Blood</i> , 2002, 100, 3108-3114.	1.4	209
11	Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. <i>Blood</i> , 2006, 107, 1724-1730.	1.4	169
12	The Src-selective Kinase Inhibitor PP1 Also Inhibits Kit and Bcr-Abl Tyrosine Kinases. <i>Journal of Biological Chemistry</i> , 2003, 278, 4847-4853.	3.4	163
13	Lenalidomide downregulates the cell survival factor, interferon regulatory factor β , providing a potential mechanistic link for predicting response. <i>British Journal of Haematology</i> , 2011, 154, 325-336.	2.5	150
14	CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL. <i>Blood</i> , 2015, 126, 779-789.	1.4	148
15	Lenalidomide efficacy in activated B -- cell -- like subtype diffuse large B -- cell lymphoma is dependent upon IRF4 and cereblon expression. <i>British Journal of Haematology</i> , 2013, 160, 487-502.	2.5	141
16	Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma. <i>Cancer Cell</i> , 2016, 29, 563-573.	16.8	140
17	Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds. <i>Blood</i> , 2015, 126, 50-60.	1.4	123
18	Role of Nonmyeloablative Allogeneic Stem-Cell Transplantation After Failure of Autologous Transplantation in Patients With Lymphoproliferative Malignancies. <i>Journal of Clinical Oncology</i> , 2002, 20, 4022-4031.	1.6	119

#	ARTICLE	IF	CITATIONS
19	BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner. <i>Oncogene</i> , 1998, 16, 335-348.	5.9	108
20	Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: Disposition kinetics and pharmacology distinct from solvent-based paclitaxel. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 1097-1107.	2.0	94
21	An activin receptor A ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin. <i>British Journal of Haematology</i> , 2014, 165, 870-882.	2.5	93
22	Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. <i>British Journal of Haematology</i> , 2014, 164, 233-244.	2.5	93
23	Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 699-712.	2.3	81
24	Dynamics of telomere shortening in neutrophils and T lymphocytes during ageing and the relationship to skewed X chromosome inactivation patterns. <i>British Journal of Haematology</i> , 2000, 109, 272-279.	2.5	80
25	A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies. <i>Clinical Cancer Research</i> , 2019, 25, 90-98.	7.0	73
26	A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma. <i>Cancer</i> , 2015, 121, 3481-3490.	4.1	68
27	A review of the history, properties, and use of the immunomodulatory compound lenalidomide. <i>Annals of the New York Academy of Sciences</i> , 2011, 1222, 76-82.	3.8	67
28	Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1516-1523.	0.9	57
29	Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma. <i>British Journal of Haematology</i> , 2016, 172, 889-901.	2.5	47
30	The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRVIII-Activated Glioblastomas. <i>Clinical Cancer Research</i> , 2013, 19, 5722-5732.	7.0	46
31	Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity. <i>British Journal of Haematology</i> , 2017, 179, 399-409.	2.5	39
32	A critical evaluation of the approaches to targeted protein degradation for drug discovery. <i>Drug Discovery Today: Technologies</i> , 2019, 31, 5-13.	4.0	37
33	RAP-011 improves erythropoiesis in zebrafish model of Diamond-Blackfan anemia through antagonizing lefty1. <i>Blood</i> , 2015, 126, 880-890.	1.4	35
34	Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1663-1672.	2.4	33
35	Immunomodulatory Effects in a Phase II Study of Lenalidomide Combined with Cetuximab in Refractory KRAS-Mutant Metastatic Colorectal Cancer Patients. <i>PLoS ONE</i> , 2013, 8, e80437.	2.5	28
36	Shwachman-Diamond Syndrome is not necessary for the terminal maturation of neutrophils but is important for maintaining viability of granulocyte precursors. <i>Experimental Hematology</i> , 2007, 35, 579-586.	0.4	21

#	ARTICLE	IF	CITATIONS
37	Differential effects of lenalidomide during plasma cell differentiation. <i>Oncotarget</i> , 2016, 7, 28096-28111.	1.8	19
38	AmBisome in the treatment of fungal infections: the UK experience. <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 49, 43-47.	3.0	15
39	Phenotypic screening with target identification and validation in the discovery and development of E3 ligase modulators. <i>Cell Chemical Biology</i> , 2021, 28, 283-299.	5.2	15
40	A Dual Color Immunohistochemistry Assay for Measurement of Cereblon in Multiple Myeloma Patient Samples. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2016, 24, 695-702.	1.2	13
41	SimPLIT: Simplified Sample Preparation for Large-Scale Isobaric Tagging Proteomics. <i>Journal of Proteome Research</i> , 2022, 21, 1842-1856.	3.7	9
42	CC-122 Degrades the Lymphoid Transcription Factor Aiolos (IKZF3) By Modulating Cereblon and Shows Clinical Activity in a Phase Ib Study of Subjects with Relapsed or Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma. <i>Blood</i> , 2014, 124, 3500-3500.	1.4	8
43	A First In Human Dose Escalation Study Of CC-122, A First-In-Class Pleiotropic Pathway Modulator, a PPM Compound In Subjects With Relapsed Or Refractory Solid Tumors, Multiple Myeloma and Non-Hodgkin's Lymphoma. <i>Blood</i> , 2013, 122, 2905-2905.	1.4	5
44	Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2013, 31, 8522-8522.	1.6	5
45	IMiDs® Immunomodulatory Agents Regulate Interferon-Stimulated Genes through Cereblon-Mediated Aiolos Destruction in Multiple Myeloma (MM) Cells: Identification of a Novel Mechanism of Action and Pathway for Resistance. <i>Blood</i> , 2014, 124, 3432-3432.	1.4	4
46	Mislocalization or low expression of mutated Shwachman-Bodian Diamond syndrome protein. <i>International Journal of Hematology</i> , 2011, 94, 54-62.	1.6	3
47	Targeting the Wnt/β2-Catenin Signaling Pathway and CD44-Mediated Adhesion As a Rational Approach to Overcome Lenalidomide Resistance in Multiple Myeloma. <i>Blood</i> , 2011, 118, 928-928.	1.4	2
48	Sotatercept, An Activin Receptor-2a Ligand Trap, Modulates Hepcidin Levels In Primary Human Hepatocytes. <i>Blood</i> , 2013, 122, 3441-3441.	1.4	1
49	Reply to "Assembling the brain trust: the multidisciplinary imperative in neuro-oncology". <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 522-523.	27.6	0
50	Results of Alemtuzumab-Based Reduced-Intensity Allogeneic Transplantation for Advanced Chronic Lymphocytic Leukemia: A BSBMT Study.. <i>Blood</i> , 2005, 106, 2899-2899.	1.4	0